Latest News

Notice of Annual General Meeting

07 May 2019

Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS.

Read more

PDMR dealings

02 May 2019

Tiziana announces that on 1 May 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note 11 to Rule 9.1 of the City Code on Takeovers and Mergers.

Read more

Update on IND Application for Oral Formulation of Foralumab for Treatment of NASH

01 May 2019

Tiziana announces an update regarding its Investigational New Drug application to the FDA to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers.

Read more

PDMR dealings

25 April 2019

Tiziana announces that on 25 April 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought American Depositary Shares each representing 10 ordinary shares of nominal value 3p each in the capital of the Company

Read more

Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Trial with milciclib in Advanced Liver Cancer Patients

24 April 2019

80% of patients who completed treatment within the trial’s timeframe requested to continue treatment on compassionate use grounds

Read more

TR-1 – Notification of Major Holdings

16 April 2019

Tiziana, a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today releases the TR-1 forms appended to this announcement.

Read more

Page 1 of 4 Next